- Home
- AMLX vs GENI Comparison
AMLX vs GENI Comparison
Compare AMLX & GENI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMLX | GENI |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMLX | GENI |
|---|---|---|
| Price | $19.37 | $6.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 16 |
| Target Price | ★ $21.56 | $12.75 |
| AVG Volume (30 Days) | 1.6M | ★ 4.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $380,786,000.00 | N/A |
| Revenue This Year | N/A | $24.00 |
| Revenue Next Year | N/A | $20.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1612.94 | N/A |
| 52 Week Low | $7.48 | $3.83 |
| 52 Week High | $20.90 | $13.73 |
Technical Indicators
Market Signals| Indicator | AMLX | GENI |
|---|---|---|
| Relative Strength Index (RSI) | 59.66 | 56.92 |
| Support Level | $12.14 | $5.55 |
| Resistance Level | N/A | $6.95 |
| Average True Range (ATR) | 1.28 | 0.38 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 68.10 | 59.55 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas: Sports Technology and Services; Betting Technology, Content, and Services; and Media Technology, Content, and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content, and Services division. Geographically, the company derives a majority of its revenue from America.